Effects on atropine on atrial refractoriness and its dispersion in humans

A. Michelucci, L. Padeletti, G. A. Fradella, R. Molina Lova, D. Monizzi, A. Giomi, F. Fantini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To evaluate the influence of atropine on atrial refractoriness and its dispersions, we studied ten subjects with sinus bradycardia who were otherwise healthy. Effective and functional refractory periods were measured at three sites of the right atrium (high, middle, and low in the lateral wall), in sinus rhythm and during atrial pacing (120/min), before and after i.v. administration of 0.04 mg/kg of atropine. Both before and after administration, dispersion of atrial refractoriness was determined from the range of refractory periods measured at the three atrial sites as the longest minus the shortest refractory period. Our data indicate that atropine was able to significantly reduce refractoriness and its dispersion. The study protocol allowed us to exclude the possibility that cycle length played a role. The antivagal effect of atropine seemed to explain our findings, even if the possibility that the drug had a direct effect could not be excluded.

Original languageEnglish
Pages (from-to)254-258
Number of pages5
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume22
Issue number5
Publication statusPublished - 1984

Fingerprint

Atropine
Refractory materials
Bradycardia
Heart Atria
Dispersions
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Michelucci, A., Padeletti, L., Fradella, G. A., Molina Lova, R., Monizzi, D., Giomi, A., & Fantini, F. (1984). Effects on atropine on atrial refractoriness and its dispersion in humans. International Journal of Clinical Pharmacology Therapy and Toxicology, 22(5), 254-258.

Effects on atropine on atrial refractoriness and its dispersion in humans. / Michelucci, A.; Padeletti, L.; Fradella, G. A.; Molina Lova, R.; Monizzi, D.; Giomi, A.; Fantini, F.

In: International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 22, No. 5, 1984, p. 254-258.

Research output: Contribution to journalArticle

Michelucci, A, Padeletti, L, Fradella, GA, Molina Lova, R, Monizzi, D, Giomi, A & Fantini, F 1984, 'Effects on atropine on atrial refractoriness and its dispersion in humans', International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 22, no. 5, pp. 254-258.
Michelucci A, Padeletti L, Fradella GA, Molina Lova R, Monizzi D, Giomi A et al. Effects on atropine on atrial refractoriness and its dispersion in humans. International Journal of Clinical Pharmacology Therapy and Toxicology. 1984;22(5):254-258.
Michelucci, A. ; Padeletti, L. ; Fradella, G. A. ; Molina Lova, R. ; Monizzi, D. ; Giomi, A. ; Fantini, F. / Effects on atropine on atrial refractoriness and its dispersion in humans. In: International Journal of Clinical Pharmacology Therapy and Toxicology. 1984 ; Vol. 22, No. 5. pp. 254-258.
@article{29a05e87358044b9a17810988dcc59dc,
title = "Effects on atropine on atrial refractoriness and its dispersion in humans",
abstract = "To evaluate the influence of atropine on atrial refractoriness and its dispersions, we studied ten subjects with sinus bradycardia who were otherwise healthy. Effective and functional refractory periods were measured at three sites of the right atrium (high, middle, and low in the lateral wall), in sinus rhythm and during atrial pacing (120/min), before and after i.v. administration of 0.04 mg/kg of atropine. Both before and after administration, dispersion of atrial refractoriness was determined from the range of refractory periods measured at the three atrial sites as the longest minus the shortest refractory period. Our data indicate that atropine was able to significantly reduce refractoriness and its dispersion. The study protocol allowed us to exclude the possibility that cycle length played a role. The antivagal effect of atropine seemed to explain our findings, even if the possibility that the drug had a direct effect could not be excluded.",
author = "A. Michelucci and L. Padeletti and Fradella, {G. A.} and {Molina Lova}, R. and D. Monizzi and A. Giomi and F. Fantini",
year = "1984",
language = "English",
volume = "22",
pages = "254--258",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0174-4879",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "5",

}

TY - JOUR

T1 - Effects on atropine on atrial refractoriness and its dispersion in humans

AU - Michelucci, A.

AU - Padeletti, L.

AU - Fradella, G. A.

AU - Molina Lova, R.

AU - Monizzi, D.

AU - Giomi, A.

AU - Fantini, F.

PY - 1984

Y1 - 1984

N2 - To evaluate the influence of atropine on atrial refractoriness and its dispersions, we studied ten subjects with sinus bradycardia who were otherwise healthy. Effective and functional refractory periods were measured at three sites of the right atrium (high, middle, and low in the lateral wall), in sinus rhythm and during atrial pacing (120/min), before and after i.v. administration of 0.04 mg/kg of atropine. Both before and after administration, dispersion of atrial refractoriness was determined from the range of refractory periods measured at the three atrial sites as the longest minus the shortest refractory period. Our data indicate that atropine was able to significantly reduce refractoriness and its dispersion. The study protocol allowed us to exclude the possibility that cycle length played a role. The antivagal effect of atropine seemed to explain our findings, even if the possibility that the drug had a direct effect could not be excluded.

AB - To evaluate the influence of atropine on atrial refractoriness and its dispersions, we studied ten subjects with sinus bradycardia who were otherwise healthy. Effective and functional refractory periods were measured at three sites of the right atrium (high, middle, and low in the lateral wall), in sinus rhythm and during atrial pacing (120/min), before and after i.v. administration of 0.04 mg/kg of atropine. Both before and after administration, dispersion of atrial refractoriness was determined from the range of refractory periods measured at the three atrial sites as the longest minus the shortest refractory period. Our data indicate that atropine was able to significantly reduce refractoriness and its dispersion. The study protocol allowed us to exclude the possibility that cycle length played a role. The antivagal effect of atropine seemed to explain our findings, even if the possibility that the drug had a direct effect could not be excluded.

UR - http://www.scopus.com/inward/record.url?scp=0021349993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021349993&partnerID=8YFLogxK

M3 - Article

C2 - 6746148

AN - SCOPUS:0021349993

VL - 22

SP - 254

EP - 258

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0174-4879

IS - 5

ER -